A Humanitarian Device Exemption Treatment Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma in Patients With Portal Vein Thrombosis

Status
Active
Cancer Type
Liver Cancer
Trial Phase
Eligibility
18 and over, Male and Female
Study Type
Treatment
NCD ID
NCT01556282
Protocol IDs
00015167 (primary)
Study Sponsor
Winship Cancer Institute of Emory University

Summary

Therasphere will be administered via catheter through the Hepatic Artery to treat patients with Hepatocellular Carcinoma and Portal vein Thrombosis.

Objectives

Therasphere consists of glass microspheres containing a radioactive material called Yttrium-90.

Therasphere is delivered into the liver tumor through a catheter placed into the hepatic artery which is the artery that provides the main blood supply to the tumor, this way delivering the radioactive material directly to the tumor and sparing the rest of the liver tissue from radiation.

Treatment Sites in Georgia


Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

Study Coordinator:
Maria Rivas
(404) 712-7962

Doctors:

Kevin Kim MD